Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aar pharma gmbh & co.kg - troxerutin - überzogene tablette - troxerutin 300.mg

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ranvet pty. limited - rutin - unknown - rutin flavour active 0.0 - active constituent

Israel - engelsk - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 50 mg - voriconazole - voriconazole - treatment of:- invasive aspergillosis,- fluconazole-resistant serious invasive candida infections (including c. krusei) - serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

Israel - engelsk - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 200 mg - voriconazole - voriconazole - treatment of: - invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei),- serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

USA - engelsk - NLM (National Library of Medicine)

bioactive nutritional, inc. - rutin (unii: 5g06tvy3r7) (rutin - unii:5g06tvy3r7) - for temporary relief of joint pain, bruising, sinus congestion, constipation, hay fever, irritability and nasal congestion.   for temporary relief of joint pain, bruising, sinus congestion, constipation, hay fever, irritability and nasal congestion.  

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ibrutinib 140mg;  ;   - film coated tablet - 140 mg - active: ibrutinib 140mg     excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 85f210036 povidone sodium laurilsulfate - imbruvica is indicated for the treatment of · patients with mcl who have received at least one prior therapy

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ibrutinib 280mg;  ;   - film coated tablet - 280 mg - active: ibrutinib 280mg     excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry purple 85f200011 povidone sodium laurilsulfate - imbruvica is indicated for the treatment of · patients with mcl who have received at least one prior therapy

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ibrutinib 420mg;  ;   - film coated tablet - 420 mg - active: ibrutinib 420mg     excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 85f210036 povidone sodium laurilsulfate - imbruvica is indicated for the treatment of · patients with mcl who have received at least one prior therapy

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ibrutinib 560mg;  ;   - film coated tablet - 560 mg - active: ibrutinib 560mg     excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 85f32547 povidone sodium laurilsulfate - imbruvica is indicated for the treatment of · patients with mcl who have received at least one prior therapy

Israel - engelsk - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 200 mg - voriconazole - treatment of: - invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei),- serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.